Abstract
Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly based on the infusion of tumor-specific T lymphocytes capable of recognizing determined MHC-restricted tumor associated antigens (TAA) through their T cell receptor. MHC-unrestricted approaches do not target specific tumor associated antigens and are mainly mediated by effectors of the innate immune system, like natural killer (NK) cells or NKT cells, first barrier against pathogens and tumorigenesis processes, or by ex vivo activated lymphocytes like cytokine-induced killer (CIK) cells. MHC-unrestricted effectors are usually more abundant than TAA-specific precursors and easier to expand. Furthermore their activity is not restricted to precise HLAhaplotypes, not limited to a single tumor histotype and could overcome downregulation of MHC molecules operated by tumor cells as immune escape mechanism.
In this review we will discuss the main cancer immunotherapy strategies based on MHC-unrestricted immune effectors. The topic will be approached from the angle of ex vivo expansion protocols in clinical prospective, as well as potential approaches to favorably modulate their functions.
Keywords: Adoptive immunotherapy, MHC-unrestricted activity, NK, CIK, NKT.
Anti-Cancer Agents in Medicinal Chemistry
Title:Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy
Volume: 14 Issue: 2
Author(s): Valeria Leuci, Giulia Mesiano, Loretta Gammaitoni, Maja Todorovic, Lidia Giraudo, Fabrizio Carnevale-Schianca, Massimo Aglietta and Dario Sangiolo
Affiliation:
Keywords: Adoptive immunotherapy, MHC-unrestricted activity, NK, CIK, NKT.
Abstract: Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly based on the infusion of tumor-specific T lymphocytes capable of recognizing determined MHC-restricted tumor associated antigens (TAA) through their T cell receptor. MHC-unrestricted approaches do not target specific tumor associated antigens and are mainly mediated by effectors of the innate immune system, like natural killer (NK) cells or NKT cells, first barrier against pathogens and tumorigenesis processes, or by ex vivo activated lymphocytes like cytokine-induced killer (CIK) cells. MHC-unrestricted effectors are usually more abundant than TAA-specific precursors and easier to expand. Furthermore their activity is not restricted to precise HLAhaplotypes, not limited to a single tumor histotype and could overcome downregulation of MHC molecules operated by tumor cells as immune escape mechanism.
In this review we will discuss the main cancer immunotherapy strategies based on MHC-unrestricted immune effectors. The topic will be approached from the angle of ex vivo expansion protocols in clinical prospective, as well as potential approaches to favorably modulate their functions.
Export Options
About this article
Cite this article as:
Leuci Valeria, Mesiano Giulia, Gammaitoni Loretta, Todorovic Maja, Giraudo Lidia, Carnevale-Schianca Fabrizio, Aglietta Massimo and Sangiolo Dario, Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660371
DOI https://dx.doi.org/10.2174/18715206113136660371 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy The Roles of Antimicrobial Peptides in Innate Host Defense
Current Pharmaceutical Design Gabapentin Antioxidant Derivatives with Anti-Inflammatory and Neuroprotective Potency
Letters in Drug Design & Discovery Editorial (Hot Topic: Vitamin D Deficiency and Critical Illness)
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Allergic Rhinitis in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry COPD: Optimal Current Treatment Strategies and Promising New Therapeutic Modalities
Current Respiratory Medicine Reviews Improving the Embryo Implantation Via Novel Molecular Targets
Current Drug Targets Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy Patent Selections
Recent Patents on Food, Nutrition & Agriculture Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia
CNS & Neurological Disorders - Drug Targets Metabolomics and Its Practical Value in Pharmaceutical Industry
Current Drug Metabolism Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Modafinil: A Useful Medication for Cocaine Addiction? Review of the Evidence from Neuropharmacological, Experimental and Clinical Studies
Current Drug Abuse Reviews